A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

Trial Profile

A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs RX 0201 (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 08 Feb 2018 According to a Rexahn Pharmaceuticals media release, the company plans to discontinue the internally funded programs of Archexin in Renal Cell Carcinoma and will cease enrollment of this trial. Patients currently enrolled in the trial will continue to be followed.
    • 08 Feb 2018 Status changed from recruiting to discontinued, as reported in a Rexahn Pharmaceuticals media release.
    • 26 Sep 2017 Planned number of patients changed from 39 to 23.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top